Logo
Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome to ShareScene - Talk Shares And Take Stock With Australia's Sharemarket Community - New Here? Click To Register >

Important Notice For All Members - ShareScene Is Moving

9 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

RMD, RESMED INC
nipper
post Posted: Dec 4 2018, 09:40 PM
  Quote Post


Posts: 5,039
Thanks: 1878


QUOTE
Resmed chief executive Mick Farrell says the acquisition of an innovative start-up that helps sufferers of asthma and other respiratory diseases allows the medical device maker to extend its growing software push into the lucrative area of pharmaceuticals for the first time.

The company spent $US225 million ($305 million) on the Wisconsin-based Propeller Health, which produces small sensors for inhalers that pair with software to provide analytics and medication alerts for people with respiratory conditions.

Mr Farrell said medical devices, on which ResMed has built its $22 billion business, accounted for just 20 per cent of healthcare expenditure. "We have a pretty good share of that 20 per cent and this will get us into the other 80 per cent," he said.....

Mr Farrell said that though Propeller's hardware was important, the value of the business was in the software. By using an intuitive consumer-facing app that draws upon data analytics, patients using Propeller's technology improved their adherence to treatment regimes by 58 per cent, he said.

Asked whether ResMed would make further acquisitions in pharmaceuticals, Mr Farrell said there were no immediate plans. "I never say never, but this one made a whole lot of sense," he said.

The acquisition expands ResMed's exposure to sufferers of chronic obstructive pulmonary disease (COPD). Some patients who suffer severely use ResMed's ventilation machines, as compared to those with lower severity levels who just use an inhaler. Propeller will also introduce ResMed to asthma sufferers for the first time....

Cloud-based medical technology, while unlocking new possibilities for connectivity and digital analytics, creates distinctive challenges around data privacy.

"We now have 3 billion nights worth of medical data," Mr Farrell said of data collected from users of ResMed's web-connected sleep therapy devices.

He estimated that ResMed had two or three times the volume of data on sleep apnoea and COPD as his competitors. "We believe in making sure we're highly vigilant, and that we have a good response if something were to happen," he said.

But Mr Farrell said that a commitment to cyber-security was not antithetical to growing apace. "It's not going to stop us from doing great innovation," he said.

Propeller was a known quantity to ResMed, which had taken out a minority stake in the smaller company. Mr Farrell had personally spent time with Propeller's team at its headquarters in Madison, Wisconsin. ResMed said they sought to maintain a balance between external acquisitions and internal research and development.

"You could do anything if you had enough time and money," Mr Farrell said. "This company had really made something innovative in something we're not in: a digital health platform for pharmaceuticals."

Once the acquisition is finalised in March 2019, Propeller will operate as a standalone business within ResMed's Respiratory Care portfolio.

Asked about the autonomy afforded to Propeller, Mr Farrell said the strategic and cultural fit between the two companies was key to his decision. "I don't want to slow them down," he said.

While Mr Farrell said the acquisition was a sound business decision, he also drew a more personal connection. Mr Farrell's father Peter established ResMed in 1989 "with a bit of angel funding and brought the technology out of the University of Sydney," he said. "Propeller is in a very similar place to where we were 25 years ago: they're an innovative start-up."
https://www.afr.com/business/health/resmed-...20181204-h18pqi





--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 30 2017, 02:33 PM
  Quote Post


Posts: 5,039
Thanks: 1878


QUOTE
RMD reported continued growth in sales of their airflow generator ("flow-gen") machines, however it exceeded expectations on mask sales.

RMD's new mask was launched only late in the quarter and had not been expected to make a meaningful contribution this early.

This bodes well given that masks remain their highest-margin product.

At the same time, the market's fears regarding price deterioration as a result of Medicare collective bidding in the US have not come to pass, potentially removing what has become a significant overhang for the stock in recent years.
BT




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 5 2017, 02:35 PM
  Quote Post


Posts: 5,039
Thanks: 1878


ResMed has hit a new milestone after one billion nights of sleep data was downloaded using its remote patient monitoring platform, AirView.

ResMed chief executive Mick Farrell said reaching one billion nights was about more than just big data.

“It is a testament to how the adoption and meaningful use of technology benefits patients, physicians and providers everywhere and we couldn’t be more pleased to start 2017 with this exciting news – this is just the beginning,” he said.

“This unprecedented amount of data enables predictive analytics to help physicians and providers better manage patients’ sleep apnoea and COPD therapy and ultimately improve their overall health.”

ResMed first enabled physicians and sleep specialists to remotely monitor sleep apnoea patients in 2004 and since then the data has helped doctors quickly identify which patients were experiencing therapy issues.

The Australian

.... So, which is worth more; the devices or the data?



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne

Said 'Thanks' for this post: early birds  
 
mullokintyre
post Posted: Apr 27 2015, 10:46 AM
  Quote Post


Posts: 1,612
Thanks: 574


In Reply To: mullokintyre's post @ Apr 24 2015, 01:07 PM


Courtesy of Ord Minett

QUOTE
Resmed (RMD) posted a net profit $91 m, up 1% but missed our forecasts by 7%.
The miss was due in part to gross margin (GM) weakness and foreign exchange,
which we expect will reverse in 3-6 months. It also offset an extraordinary validation
of RMD’s latest Flow Generator (FG) platforms that posted 42% growth in the US.
Momentum is clearly building at the top line as more recent launches (Aircurve and
Astral) ramp up and especially if the Serve HF data is as compelling as it sounds for
ventilator use amongst cardio/respiratory patients. With strong top line potential and
a GM that should correct, we maintain our Accumulate recommendation &
upgrade price target to $9.70 despite a mask segment that is struggling to
rebound.

Will hold until something else comes along that offers better.
Mick



--------------------
sent from my Olivetti Typewriter.
 
mullokintyre
post Posted: Apr 24 2015, 01:07 PM
  Quote Post


Posts: 1,612
Thanks: 574


In Reply To: promnian's post @ Apr 24 2015, 12:50 PM

Quarterly earnings released yesterday. Obviously market expected a lot better. Eps up only 2%
Revenue up 6% but gross margins were down, partially due to currency, partially due to price pressures.
Didnz't think ut was wort an 8% haircut.
Will wait for analysts views.
Mick




--------------------
sent from my Olivetti Typewriter.

Said 'Thanks' for this post: early birds  
 
promnian
post Posted: Apr 24 2015, 12:50 PM
  Quote Post


Posts: 15
Thanks: 1


In Reply To: oldgolfer's post @ Jan 15 2015, 01:24 PM

down 8% today does any one know why

thans

 


oldgolfer
post Posted: Jan 15 2015, 01:24 PM
  Quote Post


Posts: 403
Thanks: 7


In Reply To: mullokintyre's post @ Nov 28 2014, 03:45 PM

Hi Mullokintyre

Gee the resmed is doing really nicely; going to hang on to them at this stage. Bet you were pleased to grab some more a month ago. Most of the health stocks to expensive to buy now. In fact I find most of the stocks I like are too dear to buy at present and my specie is below what I paid for it.So only what low risk purchases

rolleyes.gif









 
mullokintyre
post Posted: Nov 28 2014, 03:45 PM
  Quote Post


Posts: 1,612
Thanks: 574


In Reply To: oldgolfer's post @ Nov 28 2014, 10:08 AM

I have added to my existing holdings of Resmed today.
Like the health sector.
Mick



--------------------
sent from my Olivetti Typewriter.
 
oldgolfer
post Posted: Nov 28 2014, 10:08 AM
  Quote Post


Posts: 403
Thanks: 7


In Reply To: batikit's post @ Nov 15 2013, 03:51 PM

Arty,

what does your graph reading say now? I,m not a good interp of the graphs but it looks like it could rise a bit further on this run

Did you buy in at the bottom?




 
batikit
post Posted: Nov 15 2013, 03:51 PM
  Quote Post


Posts: 498
Thanks: 59


In Reply To: arty's post @ Nov 15 2013, 01:12 PM

yes i guess it is
but i am a bit worry of the gap after the second bottom...

 
 


9 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING